NasdaqGS - Nasdaq Real Time Price • USD
Codexis, Inc. (CDXS)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:54 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | -0.18 | -0.2 | -0.65 | -0.68 |
| Low Estimate | -0.22 | -0.22 | -0.74 | -0.83 |
| High Estimate | -0.14 | -0.18 | -0.57 | -0.53 |
| Year Ago EPS | -0.34 | -0.17 | -1.12 | -0.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | 13.81M | 12.98M | 65.38M | 62.05M |
| Low Estimate | 11.79M | 11.39M | 58.88M | 51M |
| High Estimate | 15M | 15.2M | 71M | 72.5M |
| Year Ago Sales | 12.98M | -- | 70.14M | 65.38M |
| Sales Growth (year/est) | 6.40% | -- | -6.80% | -5.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.31 | -0.21 | -0.32 | -0.12 |
| EPS Actual | -0.34 | -0.17 | -0.5 | -0.1 |
| Difference | -0.03 | 0.04 | -0.18 | 0.02 |
| Surprise % | -9.70% | 19.00% | -56.20% | 16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.18 | -0.2 | -0.65 | -0.68 |
| 7 Days Ago | -0.18 | -0.2 | -0.65 | -0.68 |
| 30 Days Ago | -0.18 | -0.2 | -0.65 | -0.68 |
| 60 Days Ago | -0.19 | -0.17 | -0.67 | -0.59 |
| 90 Days Ago | -0.19 | -0.17 | -0.67 | -0.59 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CDXS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 47.10% | -- | -- | 0.80% |
| Next Qtr. | -17.60% | -- | -- | 9.60% |
| Current Year | 42.00% | -- | -- | 4.50% |
| Next Year | -4.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Upgrade | Benchmark: Hold to Buy | 2/29/2024 |
| Downgrade | Benchmark: Buy to Hold | 11/7/2023 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/6/2023 |
| Reiterates | Benchmark: Buy to Buy | 9/1/2023 |
| Maintains | Stifel: Buy to Buy | 8/14/2023 |
| Reiterates | Stephens & Co.: Overweight to Overweight | 7/21/2023 |
Related Tickers
CNTB Connect Biopharma Holdings Limited
1.5200
-1.94%
CDTX Cidara Therapeutics, Inc.
0.7220
-0.03%
RIGL Rigel Pharmaceuticals, Inc.
1.0500
-5.41%
ABIO ARCA biopharma, Inc.
3.2500
+1.25%
TSHA Taysha Gene Therapies, Inc.
2.4100
-1.63%
NRXP NRx Pharmaceuticals, Inc.
3.0200
-27.58%
EYEN Eyenovia, Inc.
0.5309
-1.56%
GLMD Galmed Pharmaceuticals Ltd.
0.3787
+6.05%
MIST Milestone Pharmaceuticals Inc.
1.6300
-6.86%
VINC Vincerx Pharma, Inc.
0.9000
-5.28%